From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...
Finding the best method to deliver chemotherapeutic drugs to tumor cells can be tricky. Ideally, the treatments target tumor cells while leaving healthy cells alone. Immunoliposomes could be the ...
In 1975, Georges Köhler and César Milstein, biochemists from the Medical Research Council Laboratory of Molecular Biology, published a paper in Nature about a hybridoma technology that enabled the ...
Researchers at the Hebrew University of Jerusalem have developed an innovative approach to fight antibiotic-resistant bacteria by creating a "tagging" technique that helps the immune system recognize ...
Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are transforming multiple myeloma care, with earlier use, expanded community access, and outpatient delivery models offering ...
COVID-19 patient whole blood sequencing data was analyzed for chimeric RNA using STARfusion, SoapFuse, and EricScript. Predictions found by at least two software and those containing no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results